The Drug-Specific Propensity Regarding the Acquisition of Fluoroquinolone Resistance in Escherichia coli: An in vitro Challenge and DNA Mutation Analysis
Open Access
- 1 September 2023
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 6357-6366
Abstract
Objective: Many fluoroquinolones, such as ciprofloxacin, are used clinically. We investigated the relationship between resistance acquisition and exposure duration in each drug through the exposure of fluoroquinolone to Escherichia coli clinical isolates in vitro. Methods: Eleven E. coli clinical isolates were exposed to each fluoroquinolone, ie, ciprofloxacin, levofloxacin, sitafloxacin, garenoxacin, and lascufloxacin, with the concentration of the mutant selection window for 5 days; these procedures were repeated 5-times. In addition, the DNA sequence in the quinolone-resistance determining region (QRDR) and the expression level in the drug efflux pump acrA were analyzed to determine the resistance mechanism. Results: Although resistant strains were not detected after 5 to 10 days of exposure to fluoroquinolone, after 25 days of exposure to ciprofloxacin and levofloxacin, 100% and 45% of isolates acquired resistance, respectively. Due to 25 days of exposure to sitafloxacin, garenoxacin, and lascufloxacin, MIC measurement was elevated 2- to 4096-fold for those of the parental strain, and the cross-resistance rate to levofloxacin was 72%, 54%, and 27%, respectively. In strains with high fluoroquinolone resistance, acrA overexpression was observed in addition to QRDR mutation. Conclusion: In our findings, fluoroquinolone resistance was not observed in the E. coli strain after 5- to 10-days of exposure. However, resistance acquisition was detected frequently after 15- to 25-days of exposure. Among fluoroquinolones, lascufloxacn had the least impact on the resistance acquisition in E. coli. Plain Language Summary: The need to combat quinolone-resistant E. coli is urgent. The resistance acquisition tendency of E. coli varies according to the drug used. After 25 days of exposure, 45% of E. coli showed levofloxacin resistance. Lascufloxacin may have the lowest influence on resistance acquisition to regular E. coli.Keywords
This publication has 33 references indexed in Scilit:
- Community-Associated Extended-Spectrum β-Lactamase–Producing Escherichia coli Infection in the United StatesClinical Infectious Diseases, 2012
- Etiology and Outcome of Community-Acquired Lung AbscessRespiration, 2010
- Sublethal Antibiotic Treatment Leads to Multidrug Resistance via Radical-Induced MutagenesisMolecular Cell, 2010
- Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal BacteriaThe Journal of Infectious Diseases, 2009
- Prevalence and Risk Factors for Selection of Quinolone-Resistant Escherichia coli Strains in Fecal Flora of Patients Receiving Quinolone TherapyAntimicrobial Agents and Chemotherapy, 2009
- Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacinDiagnostic Microbiology and Infectious Disease, 2009
- Single-Dose Pharmacokinetics and Penetration of BMS 284756 into an Inflammatory ExudateAntimicrobial Agents and Chemotherapy, 2002
- Impact of Fluoroquinolone Administration on the Emergence of Fluoroquinolone-Resistant Gram-Negative Bacilli from Gastrointestinal FloraClinical Infectious Diseases, 2001
- The Clinical Pharmacokinetics of LevofloxacinClinical Pharmacokinetics, 1997
- Mutagenic properties of N-cyclopropyl and N-allyl-N-nitroso compounds. Studies on the nature of alkylating speciesCarcinogenesis, 1984